Stephen J. Dutoit-Hamilton - Publications

Epstein-Barr virus infection monitoring in kidney transplant recipients (EVITA study)-investigating the clinical significance of EBV-DNAemia and the risk of early-onset PTLD.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: December 17, 2025

Circulating tumour DNA as a prognostic tool for surgically treated pancreatic ductal adenocarcinoma.

Journal: Human pathology

Published: November 06, 2025

17β-Hydroxysteroid dehydrogenases 1 and 2: potential markers for breast cancer recurrence and tamoxifen resistance among premenopausal women diagnosed with breast cancer in Denmark.

Journal: Breast cancer research : BCR

Published: September 11, 2025

Reduced Activity of Soluble Fibroblast Activation Protein (sFAP) Represents a Biomarker of Aggressive Disease in Lymphoid Malignancies.

Journal: International journal of molecular sciences

Published: August 29, 2025

Proteomic Profiling of Limited-Stage Follicular Lymphoma Reveals Differentially Expressed Proteins Linked to Disease Progression Post-Radiation Therapy.

Journal: International journal of molecular sciences

Published: July 18, 2025

Sinonasal neuroendocrine carcinoma in a previously healthy young adult male.

Journal: BMJ case reports

Published: June 27, 2025

Lymph node transcriptomic profiles suggest susceptibility to bleomycin-induced pulmonary toxicity in classic hodgkin lymphoma.

Journal: Scientific reports

Published: April 28, 2025

Epidemiological evidence for the role of puberty and immune senescence in Hodgkin lymphoma aetiology from 1992 Danish cases.

Journal: International journal of cancer

Published: April 15, 2025

Tumor-associated macrophages: potential role in skeletal involvement in classic Hodgkin lymphoma.

Journal: The journal of pathology. Clinical research

Published: March 27, 2025

Erratum to "Virtual Tissue Microarrays for Validating Digital Biomarker Analysis in Colorectal Carcinoma" (Lab Invest 105(2025) 104098).

Journal: Laboratory investigation; a journal of technical methods and pathology

Published: March 23, 2025

Alpha 2A adrenergic receptor antagonism reduces fibrosis, inflammation and portal hypertension in models of chronic liver disease.

Journal: JHEP reports : innovation in hepatology

Published: March 02, 2025

Alpha 2A adrenergic receptor antagonism reduces fibrosis, inflammation and portal hypertension in models of chronic liver disease.

Journal: JHEP reports : innovation in hepatology

Published: March 02, 2025